SMPDB

Showing 781 - 790 of 605359 pathways

SMPDB ID	Pathway Name and Description	Pathway Class	Chemical Compounds	Proteins
SMP0143173 View Pathway	Thiabendazole Drug Metabolism Action Pathway BioPAX SVG SBGN SBML PWML All files (.zip)	Drug Action	Thiabendazole
SMP0128901 View Pathway	Thermus thermophilus lysate Drug Metabolism BioPAX SVG SBGN SBML PWML All files (.zip)	Metabolic		Cystatin-B Thermus thermophilus lysate
SMP0128804 View Pathway	Thermomyces lanuginosus Drug Metabolism BioPAX SVG SBGN SBML PWML All files (.zip)	Metabolic		Cystatin-B Thermomyces lanuginosus
SMP0129931 View Pathway	Theralizumab Drug Metabolism BioPAX SVG SBGN SBML PWML All files (.zip)	Metabolic		Cystatin-B Theralizumab
SMP0174761 View Pathway	Theophylline Predicted Metabolism Pathway Metabolites of Theophylline are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Metabolic	Heme Theophylline Theophylline PIS1M1 Theophylline PIS1M2 Theophylline PIS2M1	Cytochrome P450 1A2 Cytochrome P450 2D6 Cytochrome P450 3A4 Unknown
SMP0142737 View Pathway	Theophylline Drug Metabolism Action Pathway BioPAX SVG SBGN SBML PWML All files (.zip)	Drug Action	Theophylline
SMP0129879 View Pathway	Theobroma cacao whole Drug Metabolism BioPAX SVG SBGN SBML PWML All files (.zip)	Metabolic		Cystatin-B Theobroma cacao whole
SMP0062624 View Pathway	Thenyldiamine H1-Antihistamine Action Thenyldiamine is an ethylenediamine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions. BioPAX SVG SBGN SBML PWML All files (.zip)	Drug Action	Calcium Guanosine diphosphate Guanosine triphosphate Histamine Inositol 1,4,5-trisphosphate Thenyldiamine Water ( show all show less )	1-phosphatidylinositol 4,5-bis... Guanine nucleotide-binding pro... Gβ Gγ Histamine H1 receptor Inositol 1,4,5-trisphosphate r... Nuclear factor NF-kappa-B p105... Protein kinase C beta type ( show all show less )
SMP0145284 View Pathway	Thenyldiamine Drug Metabolism Action Pathway BioPAX SVG SBGN SBML PWML All files (.zip)	Drug Action	Thenyldiamine
SMP0062894 View Pathway	Thenalidine H1-Antihistamine Action Thenalidine is a piperidine H1-antihistamine that was withdrawn from Canadian, US, and UK markets in 1963 due to concerns involving neutropenia (DB04826). H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions. BioPAX SVG SBGN SBML PWML All files (.zip)	Drug Action	Calcium Guanosine diphosphate Guanosine triphosphate Histamine Inositol 1,4,5-trisphosphate Thenalidine Water ( show all show less )	1-phosphatidylinositol 4,5-bis... Guanine nucleotide-binding pro... Gβ Gγ Histamine H1 receptor Inositol 1,4,5-trisphosphate r... Nuclear factor NF-kappa-B p105... Protein kinase C beta type ( show all show less )